Skip to main content

Ambry Genetics, FDNA Ink Deal to Integrate Technologies

NEW YORK (GenomeWeb) – Ambry Genetics announced today that it has signed an agreement to integrate its AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.

Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses, based on a database of more than 10,000 rare disease syndromes. AmbryPort 2.0 is a secure online portal for genetic test ordering, tracking, and results reporting.

According to Ambry, the integration will enable clinicians using Face2Gene to securely pass phenotypic information and insights from Face2Gene analysis to AmbryPort 2.0, and gain greater diagnostic insights from the molecular data.

Specific terms of the deal were not disclosed.

"Bringing FDNA's artificial intelligence and facial analysis technologies to Ambry Genetics is facilitating a new age in precision medicine," FDNA CEO Dekel Gelbman said in a statement. "We expect a dramatic increase in patients who find answers, increased understanding of rare diseases, and increased access for drug developers to create precision therapeutics for this large but underserved patient population."